LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
Julie R. Brahmer(Johns Hopkins University), Martin Reck(German Center for Lung Research), András Fülöp(Semmelweis University), Ticiana Leal(University of Wisconsin Carbone Cancer Center), Nir Peled(Shaare Zedek Medical Center), Maya Gottfried(Meir Medical Center), Suman Rao(MedStar Franklin Square Medical Center), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Katsuyuki Hotta(Okayama University Hospital), Bin Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Tibor Csőszi, M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ali Tafreshi, Jonathan W. Riess(University of California Davis Medical Center), Sinéad Cuffe(Cancer Trials Ireland), AE Robinson(The University of Sydney), Mary O’Brien(Royal Marsden NHS Foundation Trust), E. Jensen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rina Hui(The University of Sydney)
Cited by 96
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k